Vontobel Holding
BTAI icon

Vontobel Holding’s BioXcel Therapeutics BTAI Stock Holding History

Vontobel Holding’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,843
Closed -$1.32M – 1074
2022
Q4 		$1.32M Buy
+3,843
New +$929K 0.01% 509

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vontobel Holding's BTAI Position: Q1 2023 in Review

Vontobel Holding sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 3,843 shares — an estimated $1.32M sold.

Vontobel Holding first reported a position in BTAI in Q4 2022 and held it in 1 quarter. The position peaked at $1.32M in Q4 2022. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

  • Vontobel Holding reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Vontobel Holding sold 3,843 BioXcel Therapeutics shares in Q1 2023, an estimated $1.32M.
  • Vontobel Holding first reported a position in BioXcel Therapeutics in Q4 2022 and held it in 1 quarter.
  • Vontobel Holding's BioXcel Therapeutics position peaked at $1.32M in Q4 2022.
  • 96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on Vontobel Holding's 13F filing for Q1 2023, filed 12 Apr 2023.